摘要
目的研究在胃部恶性肿瘤患者接受治疗的过程中选择信迪利单抗结合改良DCF方案(多西他赛+顺铂+氟尿嘧啶)方案取得的临床效果。方法选取2020年3月—2023年3月苏州市第九人民医院收治的72例胃部恶性肿瘤患者作为研究对象,采用随机数表法平均分组,对照组中36例患者接受改良DCF方案来开展治疗,观察组中36例患者在接受改良DCF方案(多西他赛+顺铂+氟尿嘧啶)治疗的同时,应用信迪利单抗治疗。对比两组治疗效果。结果治疗后,观察组客观有效率为77.78%,疾病控制率为91.67%,优于对照组的52.78%、72.22%,差异有统计学意义(χ^(2)=4.963、4.560,P<0.05);同时观察组癌胚抗原、糖类抗原、干扰素、白细胞介素等指标更优,差异有统计学意义(P<0.05)。结论对于胃部恶性肿瘤患者开展治疗期间,信迪利单抗结合改良DCF方案具有良好的治疗效果。
Objective To study the clinical effect of Sintilimab combined with modified DCF regimen(docetaxel+cisplatin+fluorouracil)during the treatment of patients with gastric malignant tumors.Methods A total of seventy-two patients with gastric malignancies treated in Suzhou Ninth People's Hospital from March 2020 to March 2023 were selected as the study subjects.They were grouped averagely according to random number table method,thirty-six patients in the control group received the modified DCF regimen,and thirty-six patients in the observation group received the modified DCF regimen(docetaxel+cisplatin+fluorouracil)at the same time received Sintilimab.The treatment effects of the two groups were compared.Results After the treatment,the objective effective rate and disease control rate of the observation group were 77.78%and 91.67%,which were better than those of the control group(52.78%and 72.22%),and the difference was statistically significant(χ^(2)=4.963,4.560,P<0.05).The indexes of carcinoembryonic antigen,carbohydrate antigen,interferon and interleukin in the observation group were better,and the differences were statistically significant(P<0.05).Conclusion During the treatment of gastric malignant tumor patients,Sintilimab combined with improved DCF regimen not only has good therapeutic effect.
作者
吴小珍
胡晓波
戴盈英
WU Xiaozhen;HU Xiaobo;DAI Yingying(Department of Pharmacy,Suzhou Ninth People's Hospital,Suzhou,Jiangsu Province,215299 China)
出处
《系统医学》
2023年第18期9-12,共4页
Systems Medicine
